We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.
PRTK

Delisted

PRTK was delisted on the 20th of September, 2023.

Back to rankings

133 hedge funds and large institutions have $609M invested in Paratek Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 33 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 20

64% more call options, than puts

Call options by funds: $8.47M | Put options by funds: $5.15M

45% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 33

12% more funds holding

Funds holding: 119 → 133 (+14)

8% more capital invested

Capital invested by funds: $564M → $609M (+$45.4M)

50% less funds holding in top 10

Funds holding in top 10: 6 → 3 (-3)

Holders
133
Holders Change
+14
Holders Change %
+11.76%
% of All Funds
3.32%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
34
Increased
48
Reduced
33
Closed
20
Calls
$8.47M
Puts
$5.15M
Net Calls
+$3.32M
Net Calls Change
-$919K

Top Buyers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$17.6M
2
ECP
Empyrean Capital Partners
California
+$15.6M
3
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
+$7.97M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
+$7.33M
5
Millennium Management
Millennium Management
New York
+$7.29M

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$12.8M
2
IVM
InterWest Venture Management
California
-$12.3M
3
AC
Aisling Capital
New York
-$11.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$8.44M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
OFM
1
Omega Fund Management
Massachusetts
$65.3M – – –
BG
2
Baupost Group
Massachusetts
$60.1M – – –
BlackRock
3
BlackRock
New York
$48.4M +$867K +37,266 +2%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$36.7M – – –
A
5
Abingworth
United Kingdom
$26.1M -$6.04M -259,301 -20%
Vanguard Group
6
Vanguard Group
Pennsylvania
$23.7M +$1.8M +77,140 +9%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$23M +$17.6M +756,535 +473%
ECP
8
Empyrean Capital Partners
California
$16.8M +$15.6M +669,000 New
PAMU
9
Pictet Asset Management (UK)
United Kingdom
$16.6M +$7.33M +315,010 +91%
CWG
10
C WorldWide Group
Denmark
$16.2M +$4.79M +205,700 +47%
State Street
11
State Street
Massachusetts
$14.8M -$630K -27,061 -4%
Norges Bank
12
Norges Bank
Norway
$13.2M +$4.94M +212,323 +67%
RSCM
13
Rock Springs Capital Management
Maryland
$11.3M -$3.49M -150,000 -25%
FIG
14
Fortress Investment Group
New York
$10.9M – – –
BC
15
Broadfin Capital
New York
$10.2M +$3.01M +129,187 +47%
Deutsche Bank
16
Deutsche Bank
Germany
$9.94M -$605K -25,999 -6%
Renaissance Technologies
17
Renaissance Technologies
New York
$9.31M -$5.26M -226,011 -38%
Franklin Resources
18
Franklin Resources
California
$9.04M -$3.45M -148,066 -29%
GAI
19
General American Investors
New York
$8.71M +$931K +40,000 +13%
COPPSERS
20
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$8.6M +$7.97M +342,561 New
Millennium Management
21
Millennium Management
New York
$8.39M +$7.29M +313,144 +1,476%
Northern Trust
22
Northern Trust
Illinois
$8.22M -$48.3K -2,076 -0.6%
RA
23
Royce & Associates
New York
$7.36M +$240K +10,300 +4%
BBHC
24
Brown Brothers Harriman & Co
New York
$7.23M -$1.86M -80,000 -22%
DKCM
25
Davidson Kempner Capital Management
New York
$6.73M +$6.24M +268,001 New
1
2 3 4 5

PRTK Hedge Fund Activity: Q3 2017 in Review

133 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2017, worth a combined $609M — up 8.1% from $564M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new PRTK positions and 20 closed out — a net gain of 14 holders — while 48 added to existing stakes and 33 trimmed.

The largest buyer was Alyeska Investment Group, adding an estimated $17.6M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $12.8M sold.

  • 133 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2017, up from 119 in Q2 2017.
  • Funds reported $609M of Paratek Pharmaceuticals, Inc. stock for Q3 2017, up 8.1% quarter-over-quarter.
  • 34 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2017 and 20 closed out, a net change of +14 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2017 was Alyeska Investment Group, an estimated $17.6M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q3 2017 was Tekla Capital Management, an estimated $12.8M sold.

Based on aggregated 13F filings for Q3 2017.